tirzepatide surpass 5 Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6) SURPASS-CVOT Published: Large Trial Confirms

Tirzepatide API Supply for USA, UK & Canada Superpharma Group supports export procurement of Tirzepatide API to the USA, UK, Canada, and other international markets

Lyophilized storage Unreconstituted GHK-CU powder remains stable longest

6 CT-868, an investigational, once-daily, subcutaneously injected dual GLP-1/GIP receptor agonist currently in Phase II with the potential to be a first in class treatment for glycaemic control as an adjunct to insulin in patients living with type 1 diabetes

has tied up with Natco Pharma for the marketing of the drug

Even among the reputable telehealth providers that are riding the peptide wave, the selection is usually limited to GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro